Daily Stock Analysis, ADMS, Adamas Pharmaceuticals Inc, priceseries

Adamas Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
17.11
Close
17.28
High
17.77
Low
16.98
Previous Close
17.09
Daily Price Gain
0.19
YTD High
19.50
YTD High Date
Jan 6, 2017
YTD Low
14.23
YTD Low Date
Jan 30, 2017
YTD Price Change
0.69
YTD Gain
4.16%
52 Week High
19.50
52 Week High Date
Jan 6, 2017
52 Week Low
12.02
52 Week Low Date
Feb 25, 2016
52 Week Price Change
2.52
52 Week Gain
17.07%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 23. 2014
14.65
Jan 6. 2015
16.51
8 Trading Days
12.72%
Link
LONG
Jun 12. 2015
19.45
Jul 20. 2015
26.77
25 Trading Days
37.63%
Link
LONG
Oct 30. 2015
14.76
Nov 9. 2015
15.88
6 Trading Days
7.58%
Link
LONG
Dec 21. 2015
16.51
Jan 6. 2016
25.17
10 Trading Days
52.43%
Link
LONG
Mar 31. 2016
14.46
Apr 20. 2016
16.97
14 Trading Days
17.38%
Link
LONG
Aug 31. 2016
13.67
Sep 27. 2016
17.30
18 Trading Days
26.56%
Link
LONG
Nov 4. 2016
13.93
Nov 22. 2016
15.37
12 Trading Days
10.32%
Link
Company Information
Stock Symbol
ADMS
Exchange
NasdaqGM
Company URL
http://www.adamaspharma.com
Company Phone
510-450-3554
CEO
Gregory T. Went
Headquarters
California
Business Address
1900 POWELL ST., SUITE 750, EMERYVILLE, CA 94608
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001328143
About

Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems.

Description

Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company's lead product candidate is the ADS-5102 that is in Phase 3 clinical development for the treatment of levodopa-induced dyskinesia, a movement disorder associated with Parkinson's disease; and in a Phase 2 clinical study for the treatment of symptoms associated with various sclerosis, including walking impairment. The company's portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules. It has a licensing agreement with Forest Laboratories Holdings Limited for marketing Namzaric and Namenda XR. Adamas Pharmaceuticals, Inc. also engages in evaluating ADS-4101, an extended-release version of a single-agent compound for the treatment of epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.